Zeltia : Grupo Zeltia net attributable profit amounted to 13 million euro in 2014 (+16%)

Press_release_year_results_2014_zeltia

Grupo Zeltia net attributable profit amounted to 13 million euro in 2014 (+16%)

• Group total revenues amounted to 178 million euro (+8%).

• Net sales totalled 149.7 million euro (+5.5%), with growth in the Group's two main areas of activity: Biopharmaceuticals and Consumer Chemicals.

• Group EBITDA increased by 8%, to 25.7 million euro, to which the Oncology area contributed 34.6 million euro (+16%).

Madrid, 26 February 2015. Zeltia (Grupo Zeltia, ZEL.MC) announces today its full year results of 2014. Group total revenues amounted to 178.1 million euro in 2014, up 8% with respect to 2013 (164.7 million euro). Net sales amounted to 149.7 million euro (+5.5%). Net sales increased in both of the Group's business areas. In the oncology area, net sales by Yondelis® amounted to 76.8 million euro, reflecting growth of 5.3% with respect to 2013.
Consumer Chemicals also reported growth in 2014, with net sales of 66.6 million euro, representing an increase of 7.6% with respect to 2013.
The Group's total revenues also include 28.4 million euro due almost entirely to licensing contracts and strategic agreements with partners.
Group EBITDA amounted to 25.7 million euro, up 8% year-on-year. The oncology area was the main contributor to this growth, accounting for 34.6 million euro of consolidated EBITDA.

This improvement in operating profit was achieved despite the increase in R&D spending, which amounted to 52.5 million euro in 2014, up 23% year-on-year. Of that figure, 45.3 million euro corresponds to the oncology area.
Zeltia Group's net attributable profit amounted to 13.1 million euro, compared with
11.3 million euro in 2013 (+16%).

About Zeltia

Zeltia S.A. is a world-leading biopharmaceutical company specialised in the development of marine- based drugs for use in oncology. Grupo Zeltia consists mainly of the following companies: PharmaMar, the world-leading biotechnology company in advancing cancer care through the discovery and development of innovative marine-derived medicines; Genómica, Spain's leading molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi); and a chemical division comprising Zelnova and Xylazel, two highly profitable companies that are leaders in their respective market segments.

For more information [phone]
This note is also available on the Zeltia web site: www.zeltia.com